Brief: Botanix Pharmaceuticals Says FDA Confirms Approach To Sofdra™ NDA Resubmission And Materials Required
04/12/2023 01:37
Dec 4 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX :
* FDA CONFIRMS APPROACH TO SOFDRA™ NDA RESUBMISSION AND
MATERIALS
REQUIRED
Source text for Eikon: ID:nASX2pG7cr
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million